LOS ANGELES, April 17 (Reuters) - An experimental cancer drug being developed by AstraZeneca Plc failed to show effectiveness against a type of brain cancer in a mid-stage clinical trial, but the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback